(Total Views: 109)
Posted On: 12/03/2021 2:10:47 PM
Post# of 89346
$BMY News Article - U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia https://marketwirenews.com/news-releases/u-s-...05317.html
(0)
(0)
My Twitter: WhyteStocks
